Leading Regenerative Medicine Materials Company Nuoyi Mai'er Completes Nearly RMB 300 Million Series C Financing

Jan 14, 2025 17:28 CST Updated 17:29

Neo Modulus

Developer of Human Tissue Repair and Organ Regeneration Products

Instrument Family

Medical Device Media Reporting Pioneer

Share Professional Medical Device Knowledge

Focus

Source: Neo Modulus

Recently,Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. (hereinafter referred to as "Neo Modulus"), a leading enterprise in the field of regenerative medicine materials in China, announced the completion of a nearly 300 million yuan C-round financing. This round of financing was led by Shenzhen Capital Group's Manufacturing Transformation and Upgrading New Materials Fund (referred to as "Shenzhen Capital Group"), with participation from some existing shareholders and management. WinX Capital served as the exclusive financial advisor for this round of financing.

The successful completion of this round of financing further demonstrates Neo Modulus's comprehensive strength and development potential in the high-end biomedical materials field. The funds will mainly be used for the commercial promotion, clinical trials, and implementation of international strategies for the company’s multiple innovative medical device products.

Neo Modulus was founded in March 2017 by a team of Chinese and German scientists led by a recipient of China's National Key Talent Program. As an innovative enterprise, it specializes in the research, development, production, and commercialization of regenerative implantable medical devices. The company adheres to the goal of independent innovation, aiming for domestic firsts and international leadership. It has mastered core technologies from advanced raw material design, proprietary equipment development, key process preparation, to clinical product applications. It has achieved industrial application of key technology routes in the field of tissue engineering materials, including electrospinning, 3D printing, and chemical synthesis. Its diverse product portfolio includes membranes, bone materials, gels, agents, and microspheres, serving multiple clinical departments such as dentistry, ophthalmology, reproductive medicine, sports medicine, otolaryngology, and surgery. Neo Modulus has become one of the most comprehensive solution providers in China’s regenerative medical materials sector, offering the widest range of products and the most advanced technology.

Since its establishment, Neo Modulus has successively completed clinical trials and launched several products that are "firsts in China" or "internationally leading." In the field of dentistry, the company has obtained three Class III medical device registration certificates in China, providing comprehensive solutions for soft and hard tissue repair. Among them, "WenNuo® Gingival Repair Membrane" is the first Class III passive implant national innovative dental instrument in China, and it has already been used in benchmark hospitals such as West China Hospital of Stomatology, Sichuan University. In the field of otolaryngology, the innovative medical device "OleYoo® Expanding Hemostatic Sponge" has been utilized in multiple tertiary hospitals. Additionally, a variety of innovative products in ophthalmology, reproductive medicine, sports medicine, and surgery are currently undergoing clinical trials, with some projects having received approval under China’s National Key R&D Program. It is expected that multiple innovative Class III medical devices will be approved for marketing within the next five years. In the future, the company will accelerate product commercialization and market promotion, enabling more clinicians and patients to benefit from domestically produced innovative medical device products.

The company is simultaneously advancing its international layout, striving to become a leading enterprise in the global regenerative medicine field. In 2024, the company's innovative medical device, the Neosprout Nasal Hemostatic Sponge, successively received CE MDR and FDA approval for market launch, demonstrating that this innovative product has achieved internationally high standards in both efficacy and safety. Multiple innovative medical devices from the company are currently undergoing overseas registration and market promotion simultaneously, realizing the globalization of "Made in China" regenerative medicine materials.

Neo Modulus has established four R&D and production bases in Suzhou, Weifang, Taicang, and Shanghai, a medical center in Beijing, and an overseas laboratory in Freiburg, Germany, forming a "4+1+1" R&D and innovation structure. The company has built a total of over 30,000 square meters of cleanroom space, enabling rapid response to downstream demands. It provides reliable solutions and products for clinicians and patients while contributing continuously to local economic development and job creation.

Neo ModulusExpressed: Great thanks to the New Material Fund for its support to Neo Modulus, and also gratitude to all the existing shareholders for their trust in the company. Neo Modulus has entered a critical stage of accelerating commercialization. The company will continue to adhere to the development strategy of "Innovation + Internationalization" and provide a richer product portfolio to benefit patients worldwide.

About Shenzhen Capital Group

Shenzhen Capital Group was established in 1999 by the Shenzhen Municipal Government with capital contributions and guidance from social capital. With the mission of "discovering and building great enterprises," the company is committed to being an explorer and nurturer of innovative value. It has now developed into a comprehensive investment group centered on venture capital, managing a total fund size exceeding 480 billion yuan. The SZVC New Materials Fund for Manufacturing Transformation and Upgrading is a specific investment vehicle of the National Manufacturing Transformation and Upgrading Fund, primarily focusing on investments in the new materials sector.

END

Xinhua Medical, Sold Again

Win the bid, 70 million RMB per unit

Connex Medical Completes Over 500 Million RMB Financing

Philips, Selling "The Only One in Europe"

China's First Domestically Produced 7T MRI Installed at Nanshan Hospital

United Imaging Healthcare Makes Major Moves in North America

Chinese-Made Surgical Robot Unicorn Restarts IPO

Just now, Philips announced: Major personnel appointment

A-share listed device company, change of legal representative

Following Johnson & Johnson, Boston Scientific Enters This Field

BusinessBusiness cooperation email: qxzj@landianyiliao.com